Homocysteine level and coronary heart disease incidence

A systematic review and meta-analysis

Linda Humphrey, Rongwei (Rochelle) Fu, Kevin Rogers, Michele Freeman, Mark Helfand

Research output: Contribution to journalArticle

220 Citations (Scopus)

Abstract

OBJECTIVE: To determine whether an elevated homocysteine level is an independent risk factor for the development of coronary heart disease (CHD) to aid the US Preventive Services Task Force in its evaluation of novel risk factors for incident CHD. METHODS: Studies of homocysteine and CHD were identified by searching MEDLINE (1966 through March 2006). We obtained additional articles by reviewing reference lists from prior reviews, original studies, editorials, and Web sites and by consulting experts. We included prospective cohort studies that measured homocysteine and Framingham risk factors and the incidence of CHD in the general adult population without known CHD. Each study was quality rated using criteria developed by the US Preventive Services Task Force. We conducted a meta-analysis using a random-effects model to determine summary estimates of the risk of major CHD associated with each 5-μmol/L increase in homocysteine level. The systematic review and meta-analysis were conducted between January 25, 2005, and September 17, 2007. RESULTS: We identified 26 articles of good or fair quality. Most studies found elevations of 20% to 50% in CHD risk for each increase of 5 μmol/L in homocysteine level. Meta-analysis yielded a combined risk ratio for coronary events of 1.18 (95% confidence interval, 1.10-1.26) for each increase of 5 μ mol/L in homocysteine level. The association between homocysteine and CHD was similar when analyzed by sex, length of follow-up, outcome, study quality, and study design. CONCLUSION: Each increase of 5 μmol/L in homocysteine level increases the risk of CHD events by approximately 20%, independently of traditional CHD risk factors.

Original languageEnglish (US)
Pages (from-to)1203-1212
Number of pages10
JournalMayo Clinic Proceedings
Volume83
Issue number11
DOIs
StatePublished - 2008

Fingerprint

Homocysteine
Coronary Disease
Meta-Analysis
Incidence
Advisory Committees
MEDLINE
Cohort Studies
Odds Ratio
Outcome Assessment (Health Care)
Prospective Studies
Confidence Intervals

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Homocysteine level and coronary heart disease incidence : A systematic review and meta-analysis. / Humphrey, Linda; Fu, Rongwei (Rochelle); Rogers, Kevin; Freeman, Michele; Helfand, Mark.

In: Mayo Clinic Proceedings, Vol. 83, No. 11, 2008, p. 1203-1212.

Research output: Contribution to journalArticle

@article{53c2c942cd0741bb9b457f5cf5259e89,
title = "Homocysteine level and coronary heart disease incidence: A systematic review and meta-analysis",
abstract = "OBJECTIVE: To determine whether an elevated homocysteine level is an independent risk factor for the development of coronary heart disease (CHD) to aid the US Preventive Services Task Force in its evaluation of novel risk factors for incident CHD. METHODS: Studies of homocysteine and CHD were identified by searching MEDLINE (1966 through March 2006). We obtained additional articles by reviewing reference lists from prior reviews, original studies, editorials, and Web sites and by consulting experts. We included prospective cohort studies that measured homocysteine and Framingham risk factors and the incidence of CHD in the general adult population without known CHD. Each study was quality rated using criteria developed by the US Preventive Services Task Force. We conducted a meta-analysis using a random-effects model to determine summary estimates of the risk of major CHD associated with each 5-μmol/L increase in homocysteine level. The systematic review and meta-analysis were conducted between January 25, 2005, and September 17, 2007. RESULTS: We identified 26 articles of good or fair quality. Most studies found elevations of 20{\%} to 50{\%} in CHD risk for each increase of 5 μmol/L in homocysteine level. Meta-analysis yielded a combined risk ratio for coronary events of 1.18 (95{\%} confidence interval, 1.10-1.26) for each increase of 5 μ mol/L in homocysteine level. The association between homocysteine and CHD was similar when analyzed by sex, length of follow-up, outcome, study quality, and study design. CONCLUSION: Each increase of 5 μmol/L in homocysteine level increases the risk of CHD events by approximately 20{\%}, independently of traditional CHD risk factors.",
author = "Linda Humphrey and Fu, {Rongwei (Rochelle)} and Kevin Rogers and Michele Freeman and Mark Helfand",
year = "2008",
doi = "10.4065/83.11.1203",
language = "English (US)",
volume = "83",
pages = "1203--1212",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "11",

}

TY - JOUR

T1 - Homocysteine level and coronary heart disease incidence

T2 - A systematic review and meta-analysis

AU - Humphrey, Linda

AU - Fu, Rongwei (Rochelle)

AU - Rogers, Kevin

AU - Freeman, Michele

AU - Helfand, Mark

PY - 2008

Y1 - 2008

N2 - OBJECTIVE: To determine whether an elevated homocysteine level is an independent risk factor for the development of coronary heart disease (CHD) to aid the US Preventive Services Task Force in its evaluation of novel risk factors for incident CHD. METHODS: Studies of homocysteine and CHD were identified by searching MEDLINE (1966 through March 2006). We obtained additional articles by reviewing reference lists from prior reviews, original studies, editorials, and Web sites and by consulting experts. We included prospective cohort studies that measured homocysteine and Framingham risk factors and the incidence of CHD in the general adult population without known CHD. Each study was quality rated using criteria developed by the US Preventive Services Task Force. We conducted a meta-analysis using a random-effects model to determine summary estimates of the risk of major CHD associated with each 5-μmol/L increase in homocysteine level. The systematic review and meta-analysis were conducted between January 25, 2005, and September 17, 2007. RESULTS: We identified 26 articles of good or fair quality. Most studies found elevations of 20% to 50% in CHD risk for each increase of 5 μmol/L in homocysteine level. Meta-analysis yielded a combined risk ratio for coronary events of 1.18 (95% confidence interval, 1.10-1.26) for each increase of 5 μ mol/L in homocysteine level. The association between homocysteine and CHD was similar when analyzed by sex, length of follow-up, outcome, study quality, and study design. CONCLUSION: Each increase of 5 μmol/L in homocysteine level increases the risk of CHD events by approximately 20%, independently of traditional CHD risk factors.

AB - OBJECTIVE: To determine whether an elevated homocysteine level is an independent risk factor for the development of coronary heart disease (CHD) to aid the US Preventive Services Task Force in its evaluation of novel risk factors for incident CHD. METHODS: Studies of homocysteine and CHD were identified by searching MEDLINE (1966 through March 2006). We obtained additional articles by reviewing reference lists from prior reviews, original studies, editorials, and Web sites and by consulting experts. We included prospective cohort studies that measured homocysteine and Framingham risk factors and the incidence of CHD in the general adult population without known CHD. Each study was quality rated using criteria developed by the US Preventive Services Task Force. We conducted a meta-analysis using a random-effects model to determine summary estimates of the risk of major CHD associated with each 5-μmol/L increase in homocysteine level. The systematic review and meta-analysis were conducted between January 25, 2005, and September 17, 2007. RESULTS: We identified 26 articles of good or fair quality. Most studies found elevations of 20% to 50% in CHD risk for each increase of 5 μmol/L in homocysteine level. Meta-analysis yielded a combined risk ratio for coronary events of 1.18 (95% confidence interval, 1.10-1.26) for each increase of 5 μ mol/L in homocysteine level. The association between homocysteine and CHD was similar when analyzed by sex, length of follow-up, outcome, study quality, and study design. CONCLUSION: Each increase of 5 μmol/L in homocysteine level increases the risk of CHD events by approximately 20%, independently of traditional CHD risk factors.

UR - http://www.scopus.com/inward/record.url?scp=55549115068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549115068&partnerID=8YFLogxK

U2 - 10.4065/83.11.1203

DO - 10.4065/83.11.1203

M3 - Article

VL - 83

SP - 1203

EP - 1212

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 11

ER -